Generic Drugs News: October 2006 Archives

October 24, 2006 (Toronto, ON) - Substitution of generic warfarin for brand-name warfarin (Coumadin, Bristol-Myers Squibb) has no appreciable effect on rates of INR testing or hospitalization for adverse events, a new analysis suggests. In a research letter appearing in the October 25, 2006 issue of the Journal of the American Medical Association, J Michael Paterson and colleagues report that switching to either Apo-warfarin or Taro-warfarin was also associated with significant cost savings.

J&J Gets Injunction Against Mylan


ITUSVILLE, N.J. (AP) - Diversified health care and consumer products maker Johnson & Johnson said Tuesday its Ortho-McNeil Neurologics Inc. division was granted a preliminary injunction against Mylan Laboratories Inc. preventing it from launching a generic version of topiramate before a final court ruling on the validity of the patent.

Judge Stanley R. Chesler of the U.S. District Court for the District of New Jersey in Newark, N.J., granted the injunction on Monday for Ortho-McNeil's Topamax brand.

Topamax is used for epilepsy, Lennox Gastaut syndrome and migraine headaches.

FDA to speed up review of certain generic drugs


Generic drugs are getting more and more approvals?

Companies will be given priority if their application is the first one proposing a generic version of a brand name drug that is no longer protected by a patent or market exclusivity
User fees simply won't speed up generic drug approval times if brand companies are still able to use loopholes such as citizen petitions to block consumer access to affordable generics

While I wish that Generic drugs providers will get more and more exposure and market, I think that patented pharma corporations won't give up easily.

Dr.Reddy's settles patent dispute


Indian drug maker Dr Reddy's Laboratories Ltd. said Tuesday that it may sell generic copies of popular anti-migraine pill Imitrex in the United States since it has settled a patent dispute with its manufacturer, GlaxoSmithKline Plc.

The generic drug may be launched in the last quarter of 2008, Dr Reddy's said in a filing to the Bombay Stock Exchange.

Imitrex sales in the United States totaled US$890 million in the year ended in June, the statement said.
The news lifted Dr Reddy's shares by more than 2 percent to 722 rupees in trading on the Bombay Stock Exchange.